Novavax, Inc.’s NVAX final data from a pivotal phase III study evaluating its coronavirus vaccine candidate, NVX-CoV2373, showed that it was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain in the United Kingdom.
The company also announced results from the complete analysis of its phase IIb study in South Africa. In the region marked by a vast majority of strains that are B1.351 escape variants, the vaccine candidate delivered 55.4% efficiency…
Source link
